Diversified Healthcare Trust vs Healthpeak Properties
DHC and DOC side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DHC and DOC compare
Healthpeak Properties is the larger company, worth 6.8 times as much as Diversified Healthcare Trust ($13.1B against $1.9B).
Healthpeak Properties grew revenue faster over the last twelve months (5.5% versus −1.5% for Diversified Healthcare Trust).
Healthpeak Properties keeps more of each dollar of sales as profit, with a net margin of 8.2% compared with −17.7% at Diversified Healthcare Trust.
Both pay dividends: Diversified Healthcare Trust yields 0.50% and Healthpeak Properties 6.4%.
Healthpeak Properties scores higher on the StockData Score (8 against 1 for Diversified Healthcare Trust), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DHC | DOC |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $13.1B |
| Share price | $7.97 | $19.03 |
| Change, 1 year | 91.1% | 8.2% |
| Change, 5 years | 123% | −44.4% |
| Beta (5Y) | 1.09 | 0.73 |
| Employees | 600 | 411 |
| StockData Score | ||
| Total score | 1 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 4 (better) |
| Performance score | 0 | 0 |
| Health score | 0 | 0 |
| Dividend score | 1 | 3 (better) |
| Valuation | ||
| P/E | – | 54.4× |
| P/S | 1.3× (better) | 4.4× |
| P/B | 1.2× (better) | 1.7× |
| EV/EBITDA | 14.5× | 7.0× (better) |
| Fair value | $4.45 | $17.22 |
| Margin of safety | −78.9% | −10.5% (better) |
| Growth | ||
| Revenue growth (TTM) | −1.5% | 5.5% (better) |
| Revenue growth, 5Y average | −1.2% | 11.4% (better) |
| Net income growth (TTM) | – | 47.5% |
| EPS growth (TTM) | – | 45.8% |
| EPS growth, 5Y average | – | −33.5% |
| Profitability | ||
| Net margin | −17.7% | 8.2% (better) |
| Return on equity | −15.5% | 3.1% (better) |
| Financial health | ||
| Altman Z-score | 1.13 (better) | 0.78 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.50% | 6.4% (better) |
| Payout ratio | – | 348% |
| Years of dividend growth | 0 | 1 (better) |
| Dividend growth, 5Y average | −26.0% | −3.8% (better) |
| Buyback yield | 0.06% | 0.77% (better) |
| Shareholder yield | 0.56% | 7.2% (better) |
| Ownership | ||
| Held by institutions | 84.9% | 95.9% |
| Held by insiders | 15.2% | 0.36% |
| Insider net buying, 12 months | $97.8K (better) | −$214K |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 3.4% |
Go deeper
- DHC stock overview
- DHC income statement
- DHC valuation and score
- DOC stock overview
- DOC income statement
- DOC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.